Abbott India Stock

Abbott India FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Abbott India (ABBOTINDIA.NS) as of Aug 23, 2026 is 67.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 96.94 % — a change of -30.04% (lower).

FCF Conversion

67.82 %

YoY

-30.04%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Abbott India is 2026 67.82 % . FCF Conversion Rate (FCF/EBITDA) of Abbott India was 2025 96.94 % . It decreases by -30.04% lower compared to the previous year.

The Abbott India FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
32.01 INR
Jan 1, 2019
108.07 INR
Jan 1, 2020
102.95 INR
Jan 1, 2021
101.84 INR
Jan 1, 2022
113.13 INR
Jan 1, 2023
90.51 INR
Jan 1, 2024
96.94 INR
Jan 1, 2025
67.82 INR
The Abbott India FCF Conversion history
YEARFCF ConversionYoY
67.82 %-30.04%
96.94 %+7.11%
90.51 %-20.00%
113.13 %+11.09%
101.84 %-1.07%
102.95 %-4.74%
108.07 %+237.57%
32.01 %-69.01%
103.29 %+16.71%
88.51 %+3.03%
85.90 %+24.23%
69.15 %—
Access this data via the Eulerpool API
Get Free API Key

Abbott India Stock analysis

What does Abbott India do? Abbott India Ltd is a leading pharmaceutical company in India that was founded in 1944. Abbott Laboratories, a multinational company from the USA, is the parent company of Abbott India Ltd. Abbott India Ltd is headquartered in Mumbai and specializes in the development, manufacturing, and marketing of products in the healthcare and medical technology sectors. The business model of Abbott India Ltd is based on the development of innovative products and solutions that provide value to customers. The company operates a comprehensive research and development center where it constantly works on new products and technologies to meet the needs of customers. Abbott India Ltd operates in several areas, including pharmaceuticals, diagnostics, and medical technology. The pharmaceutical division includes a wide portfolio of drugs in areas such as gastroenterology, neurology, hormones, and antibiotics. The diagnostics division of Abbott India Ltd provides advanced solutions for disease diagnosis and is a leader in diabetes management, infectious diseases, oncology, and immunology. The medical technology division produces high-quality products, including heart implants, stents, catheters, and pacemakers. Abbott India Ltd is a leading company in the production of dietary supplements and has a wide range of vitamins, minerals, and proteins in its portfolio. Some of the well-known brands of the company include Pedialyte, Similac, EAS, and PediaSure. History: Abbott India Ltd has been active in India since 1944 and has continuously expanded its business. The company started its operations as a trading company distributing vaccines, serum, and diagnostic solutions in India. Abbott India Ltd started pharmaceutical production in 1945 by establishing a pharmaceutical manufacturing facility in Mumbai. Over the years, the production facility has been modernized and expanded to meet the increasing demand for high-quality products. In the 1970s, Abbott India Ltd expanded into the field of diagnostics by introducing advanced testing solutions for healthcare in India. Abbott India Ltd was one of the first companies to introduce advanced tests for hepatitis B in India and has since been a leader in the diagnosis of infectious diseases. In the 1990s, Abbott India Ltd ventured into the field of medical technology by opening a production facility for high-quality implants in Mumbai. The company invested in manufacturing facilities and gained a strong R&D team to develop and manufacture advanced solutions for implants and medical technology in India and other countries. Today, Abbott India Ltd has over 4,000 employees and operates in more than 60 cities in India. The company has built a strong distribution and marketing network to distribute its products throughout India. Summary: Abbott India Ltd is a leading pharmaceutical company in India that offers a wide range of products and solutions for healthcare and medical technology. The company has a profound history and expertise in manufacturing high-quality products and developing advanced solutions for healthcare. Abbott India Ltd is known for its innovative products and services and will continue to play a significant role in the healthcare industry. Abbott India is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abbott India stock

FCF Conversion Rate (FCF/EBITDA) of Abbott India is 67.82 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Abbott India changed from 96.94 % to 67.82 %, representing a -30.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Abbott India since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Abbott India with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Abbott India

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Abbott India